FIRST AIRED: March 20, 2019

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



shares of sage therapeutic sort in pre market trading Wednesday after the U. S. food and drug administration approved its treatment for post partum depression it's the first approval of a drug specifically targeting the condition which affects a new mothers ability to care for herself or her baby sold under the names will rise so it's delivered through in fusion and works very quickly during clinical trials it was shown to reduce symptoms of depression within hours and some patients gained relief for up to a month and a half after word yet some women may face barriers to obtaining the treatment not least a requirement to remain at a certified Medical Center for sixty hours in case of side effects like dizziness or headaches well that sounds inconvenient one psychiatrist told Reuters that it's likely worth it for mother suffering severe post partum depression which could give rise to suicidal tendencies another barrier for mothers is the price tag the company said the average price per patient would be thirty four thousand dollars before discounts